Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Clinical trial NCT03736889 · RECRUITING

Trial details

NCT number: NCT03736889
Sponsor: BeiGene
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

MSI-H/dMMR Solid Tumors

Start date: 2018-09-19
Primary completion: 2026-11-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.